Back to Home Page
Our Physicians
What is PET/CT?
Clinical Applications
When to do a PET/CT
Scheduling & Results
Referral Form
Patient Guide
Studies
Reimbursement Info
Insurance List
Case Studies
Contact Us & Directions


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Return to top of page


Reimbursement Information

New CPT codes have been assigned by the American Medical Association (AMA) for PET and
PET/CT scanning services! In an effort to keep you informed about these updates, we have listed the new CPT codes below.

Type of Study
CPT Code
Tumor Imaging, base of skull-thigh
78815
Tumor Imaging, full body
78816
Brain Imaging, metabolic evaluation
78608
Brain Imaging, perfusion evaluation
78609
Myocardial Imaging, metabolic evaluation
78459

If you have any questions feel free to call us and we can help you properly protocol and code the study.

Oncology Clinical Indications

Brain Tumor

• Differentiate recurrent tumor from radiation necrosis
• Differentiate primary CNS lymphoma from toxoplasmosis
• Exclude metastatic disease of the brain

Breast Cancer

• Identify involved axillary nodes or distant metastatic disease
• Exclude local recurrence of disease
• Evaluate response to treatment

Cervical Cancer

• Detect pre-treatment metastases in newly diagnosed cancer

Colorectal Cancer

• Detect locally recurrent or distant metastatic disease in
patients with elevated or rising CEA who may be candidates
for surgical re-excision
• Rule out distant metastases for preoperative evaluation

Esophageal Cancer

• Evaluate local extent of disease, and exclude distant
metastases
• Evaluate disease to determine surgical appropriateness

Head & Neck Cancer

• Determine extent of local, regional, and distant disease
• Detect recurrent/residual tumor following definitive therapy

Lung Cancer

• Distinguish malignant from benign pulmonary nodules
• Stage for mediastinal or distant metastatic disease
• Use as part of radiotherapy treatment planning
• Detect recurrent/residual tumor following definitive therapy

Lymphoma

• Determine extent of disease
• Measure treatment response

Melanoma

• Identify extent of local and regional disease spread in patients
with high risk melanoma (e.g., primary tumor ≥4mm), or in
suspected recurrence

Musculoskeletal Tumors

• Evaluate local extent of disease and exclude distant
metastases
• Measure treatment response and exclude recurrent/residual
tumor following definitive therapy

Ovarian Cancer

• Detect recurrent/residual tumor prior to surgical exploration or
additional chemotherapy

Pancreatic Cancer

• Differentiation of benign processes such as pancreatitis,
mucinous cyst adenoma and pseudocyst from malignant
disease
• Rule out distant metastases for preoperative evaluation

Thyroid Cancer

• Detect metastatic or locally recurrent disease in patients with
elevated thyroglobulin after definitive initial treatment and
negative I-131 examination


References

Conti, P.S., Lilien, D.L., Howley, K., Keppler, J., Grafton, S.T., Bading, J., PET and F-18 FDG in
Oncology: A Clinical Update. Nuclear Medicine and Biology, (1996) 23:717-735.

Di Chiro, G., Positron Emission Tomography Using FDG in Brain Tumors: A Powerful
Diagnostic and Prognostic Tool. Investigational Radiology,(1986) 2:360-371.


© 2009, Metro Region PET Center, LLC. All Rights Reserved

`